Bessemer Group’s Alaunos Therapeutics TCRT Stock Holding History

Bessemer Group’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-98	Closed	-$58K	–	1787
2018 Q1	$58K	Hold	98	–	–	﹤0.01%	1218
2017 Q4	$61K	Buy	+98	New	+$70.4K	﹤0.01%	1227

Other funds holding TCRT

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bessemer Group's TCRT Position: Q2 2018 in Review

Bessemer Group sold out of Alaunos Therapeutics (TCRT) in Q2 2018, closing a stake of 98 shares — an estimated $58K sold.

Bessemer Group first reported a position in TCRT in Q4 2017 and held it in 2 quarters. The position peaked at $61K in Q4 2017. 133 funds tracked by Wall St. Rank hold TCRT as of Q2 2018.

Bessemer Group reported no remaining Alaunos Therapeutics position as of Q2 2018 after selling out during the quarter.
Bessemer Group sold 98 Alaunos Therapeutics shares in Q2 2018, an estimated $58K.
Bessemer Group first reported a position in Alaunos Therapeutics in Q4 2017 and held it in 2 quarters.
Bessemer Group's Alaunos Therapeutics position peaked at $61K in Q4 2017.
133 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2018.

Based on Bessemer Group's 13F filing for Q2 2018, filed 25 Jul 2018.